Vertex Pharmaceuticals Incorporated (VRTX) M&A Call Transcript

Vertex Pharmaceuticals Incorporated ( VRTX ) M&A Call July 6, 2026 4:30 PM EDT Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Duncan J. McKechnie - Chief Commercial Officer, Head of North America Commercial & Executive VP Charles Wagner - Executive VP, COO & CFO Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Mario Joshua Chazaro Cortes - Evercore ISI Institutional Equities, Research Division Andy Chen - Wolfe Research, LLC Jarwei Fang - Citigroup Inc., Research Division Evan Seigerman - BMO Capital Markets Equity Research Michael Yee - UBS Investment Bank, Research Division Nevin Varghese - RBC Capital Markets, Research Division Philip Nadeau - TD Cowen, Research Division Tazeen Ahmad - BofA Securities, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Jasmine Fels - Barclays Bank PLC, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Presentation Operator Good day, and welcome to the Vertex Pharmaceuticals conference call to announce the acquisition of Crinetics Pharmaceuticals. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead. Susie Lisa Senior Vice President of Investor Relations Thanks, Chuck. Good afternoon, everyone, and thank you for joining us on short notice for this exciting announcement. I'm Susie Lisa, and as Senior Vice President of Investor Relations, it's my pleasure to welcome you to this conference call to discuss Vertex's acquisition of Crinetics Pharmaceuticals. Making prepared remarks on today's call, we have Dr. Reshma Kewalramani, Vertex's CEO and President; Duncan McKechnie, Chief Commercial Officer; and Charlie Wagne...